Dr Bianca Ogden: The healthcare insider

The best opportunities are found when you don't follow the herd.
David Thornton

Livewire Markets

The traditional path into funds management usually goes something like this. Study a bachelor of commerce or economics, pass three rounds of exams to become a Chartered Financial Analyst (CFA), and then get a job as one. 

But there's another way - a path less trodden.  

You grow up with a love for the health sciences, do a PhD in virology in London, and then take roles in drug development at Novartis and Johnson & Johnson. 

Then, upon realising that drug development doesn't happen without investment, you jump the fence into funds management - as a sector insider. 

That's the heavily truncated experience of Dr Bianca Ogden, portfolio manager of the International Healthcare Fund at Platinum Asset Management. 

By her own admission: "I'm not your typical fund manager."

In conjunction with International Women's Day, Livewire reached out to some trailblazing female fund managers. In this wire, Ogden charts the course of her career, her investment philosophy, her outlook for the Biotech sector, and the reasons and remedies for gender inequality within the finance sector. 

Platinum's Dr Bianca Ogden. 
Platinum's Dr Bianca Ogden

Ogden's profile:

  • Firm: Platinum Asset Management
  • Years in the industry: 20 years
  • Specialty: Global health sciences
  • Biggest personal portfolio holding: Immunovant (NASDAQ: IMVT)
  • One thing very few people know about you: Ogden's first pet a guinea pig was called Nick, the same as her husband.
  • Your guilty secret TV or reading pleasure: Currently watching Drive to Survive, and love everything Yellowstone related. FC Bayern: She also likes the documentary Behind the Legend (as a child she had FC Bayern bedsheets!)
Source: Supplied
Source: Supplied

A journey to the dark side, literally

If anything defines Ogden's career path, it's a curiosity for the next frontier.  

At first, that frontier was HIV, a fascination that led her to study biology and gain a PhD in Virology at UCL in London.

What followed were stints in HIV and cancer drug development. 

"I was lucky to work on a new HIV drug at Novartis in Switzerland. I moved on to Johnson & Johnson here in Sydney, this time on cancer research and learnt more about how global pharmaceutical companies function and how excited they were about biotechs," Ogden recalls. 

It was at Novartis where Ogden's purview began to widen beyond research and drug development.

"At the same time, the lab next door was developing what would become one of Novartis' blockbuster cancer drugs," says Ogden. "Seeing all that first-hand made me want to understand drug development companies - I was really interested in how they make decisions."

At the time, biotechs were starting to gain some buzz in the industry. 

"The genomics bubble just happened, while financial types were all worried, the drug development industry knew that the biotech industry would grow in importance," Ogden says. 

Soon after, Platinum Asset Management founder Kerr Neilson pitched Ogden his idea for a healthcare fund. 

But like the Petri dishes she'd used countless times before, Ogden was mostly kept in the dark. 

"I said, 'Look, I don't know what funds management is, I don't know what you do every day.' And Kerr said, 'Don't worry, it's all very good'," she shares. 

"I asked if I could just come in for a day and have a look. And he said, 'No, you can't. I can employ you, but you can't just have a look.'

"And I said, well, that's really unhelpful."

As she would later find out, Neilson was concerned that the male-dominated world of managed funds would put Ogden off. 

Eight months later, with precious little to go on, she took the job with Platinum. 

A rocky start

Transitioning into funds management didn't come easy for Ogden. There was a hefty vernacular to learn, and not many women at the time used it. Simply because there were so few women in the industry. 

Then there was the actual investment side - pulling the trigger and backing a stock. For a fund manager, this is where the rubber meets the road. 

At first, the rubber didn't quite grip the tarmac.

"My first pick was Merck (NASDAQ: MRK). Two weeks after buying it the company withdrew Vioxx, a prescription drug used to treat arthritis. I thought that was the end of my analyst career!" She says. 

Ogden quickly cottoned on that setbacks are opportunities dressed up as failures. 

"Kerr was super excited and saw an opportunity! It was one of the biggest learnings in my funds management career," she recalls. 

Back yourself

Ogden's subsequent success has been grounded in the unique skillset she brings to the table. 

"It is not easy, and at times things don’t go well or feel very challenging, but perseverance and factual thinking are key," she says.  

Finance was then, and still is, a male-dominated industry. 

"No doubt funds management is male-dominated, given my technical background some will put you in a box and fail to see the strategic thinking. It is all about self-confidence and speaking up in a constructive manner. Stick to your values and who you are," she says. 

Meet, greet and question

Funds management is a data-heavy pursuit. And to an extent, there's no getting around that. 

But the numbers are just one piece of the puzzle. More often than not, the aetiology of those numbers can be traced back to human decisions.  

"Go out and talk to people in the industry, companies are not run on spreadsheets, people are at the core of companies, they make right and wrong decisions," says Ogden. 

"As a fund manager, we don’t really make the hard decisions about deploying large amounts of capital for a new project or decide to restructure because an approach has failed, make sure you listen and expose yourself to aspects you don’t know. I learn every day from the companies that I look at and they do shape my thinking."

Interacting with management also offers one of the best insights into a company's future - its plans, but also its plan Bs. 

"What are you going to do the next five years? It's not about tomorrow. You had a setback here, what are you doing about that? What's your plan B? How do you work with that? And who do you talk to?" Ogden explains. 

Finally, meeting management provides Ogden with the ability to "triangulate". 

"Let's say you talk to a range of companies in the gene therapy space at the $50 million market cap really struggling to raise money but have a product approved," she says. 

"Then you go and talk to a company that sits at a $10 billion market cap about to get a product approved. And so you try to understand the hold-up. What's happening? What are the challenges? Where do you raise money? You get a feel for what's happening in the companies.

"Then on the other side, you speak to doctors that use it or the scientists that work on it."

Outlook for markets (and some stocks to play it)

Inflation continues to grip markets, and the healthcare sector isn't immune. But Ogden reckons this should die down, with some sector consolidation to follow.

"The ongoing debate about inflation adds uncertainty, but towards the end of the year things should become clearer and I am sure we will see more M&A," she says. 

In pharmaceuticals, expiring patents equals opportunity. 

"In the coming years, there is another patent cliff upon us. Large drug developers have ample cash to spend. Get ready," she says. 

Ogden has high conviction in biotech, despite it being a beaten-down sector. 

"Biotech had a very tough year, the macro narrative has dominated and many investors ran (and still run) a mile from these companies," says Ogden. 

"What is great though is that there is quite a lot of money dedicated to this sector, we have seen some successful IPOs, we have seen solid fundraisings and we are seeing progress. Things are gradually improving." 

Ogden is also excited about the strengthening nexus between machine learning and biotech.  

"To us, the computer sciences will continue to infiltrate drug discovery over the next decade. They have pipelines coming out very quickly," she says. 

"Computer science is making great strides and without a doubt will shape drug discovery in the coming decade."

Finally, "neurology is seeing innovation, and given the macro environment, emerging life science tool companies are cheap," Ogden says. 

At the stock level, Ogden is excited about Exscientia (NASDAQ: EXAI), a UK biotech that combines computer sciences and biotech. It has an emerging pipeline, ongoing clinical trials, and various partnerships within the pharmaceutical sector. 

Ogden also offers up Takeda (NASDAQ: TAK), a Japanese pharmaceutical company that embraces biotech. 

"It knows how to integrate companies, the pipeline is emerging, and its plasma business is a steady earner," she adds. 

Managed Fund
Platinum International Health Care Fund
Global Shares
........
Livewire gives readers access to information and educational content provided by financial services professionals and companies ("Livewire Contributors"). Livewire does not operate under an Australian financial services licence and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any advice given. Any advice on this site is general in nature and does not take into consideration your objectives, financial situation or needs. Before making a decision please consider these and any relevant Product Disclosure Statement. Livewire has commercial relationships with some Livewire Contributors. Platinum Investment Management Limited ABN 25 063 565 006, AFSL 221935, trading as Platinum Asset Management (“Platinum”). This information is general in nature and does not take into account your specific needs or circumstances. You should consider your own financial position, objectives and requirements and seek professional financial advice before making any financial decisions. You should also read the latest Platinum Trust® product disclosure statement and target market determination before making any decision to acquire units in the fund, copies of which are available at www.platinum.com.au/Investing-with-Us/New-Investors. Commentary reflects Platinum’s views and beliefs at the time of preparation, which are subject to change without notice. Certain information contained in this presentation constitutes "forward-looking statements". Due to various risks and uncertainties, actual events or results, may differ materially from those reflected or contemplated in such forward-looking statements and no undue reliance should be placed on those forward-looking statements. Past performance is not a reliable indicator of future returns. To the extent permitted by law, no liability is accepted by Platinum for any loss or damage as a result of any reliance on this information.

1 fund mentioned

2 contributors mentioned

David Thornton
Content Editor
Livewire Markets

David is a content editor at Livewire Markets. He currently hosts The Rules of Investing, a half hour podcast where he sits down with leading experts across equities, fixed income and macro.

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.

Comments

Sign In or Join Free to comment